Two new investment vehicles provide capacity to finance approximately 30 biotech companies
Investors in Healthcare’s article “Netherlands – Forbion raises €2.3bn across two new life sciences venture funds” reports on Forbion’s record €2.3 billion ($2.6 billion) fundraising across Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII. The fundraising substantially exceeded its target and brings Forbion’s assets under management to approximately €7.5 billion, reinforcing the firm’s position as Europe’s largest dedicated life sciences venture capital investor by assets under management.
The coverage highlights the complementary mandates of the two funds. Growth Opportunities Fund IV will focus primarily on later-stage biopharma companies in Europe and North America developing novel therapies in areas of high medical need. Ventures Fund VIII will invest in therapeutics-focused biotech companies, including existing businesses and new ventures built around promising assets and experienced teams. Combined, the funds have the capacity to support approximately 30 high-potential portfolio companies, backed by strong participation from both existing and new institutional and corporate investors.